Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | The future of SCD and thalassemia HSCT: partially matched donors

Lawrence Faulkner, MD, Cure2Children Foundation, Florence, Italy, highlights the potential for haploidentical hematopoietic stem cell transplantation (HSCT) as a cost-effective and accessible option for treating sickle cell disease (SCD) and thalassemia. This interview was held at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.